Interpace Biosciences
Hamilton
About Interpace Biosciences
Interpace Biosciences (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Their Interpace Diagnostics business unit provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services, including such widely respected tests as PancraGen®, ThyGeNext®, ThyraMir®, RespriDX® and BarreGen®.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $70.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2020)
- Ticker: otcqx:IDXG
- Website: interpace.com
- Phone: +64 (215)525-5207
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/interpace-biosciences-177922 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.